S-8921 (Shionogi).
S-8921 is a sodium/bile acid transport inhibitor under development by Shionogi for the potential treatment of hyperlipidemia. As of June 2000, phase I trials had commenced in Japan and were planned in Europe [370602]. S-8921 acts by altering sodium-dependent transport mechanisms of the brush-borders in the intestinal mucosa, causing bile acids that re-enter the intestine to be excreted rather than reabsorbed [281476].
Booker
M L
ML
GelTex Pharmaceuticals Inc, Waltham, MA 02451, USA. mbooker@geltex.com
D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001647:Bile Acids and Salts / Q000378:metabolism*; D001692:Biological Transport / Q000187:drug effects; D002352:Carrier Proteins / Q000037:antagonists & inhibitors*; D017321:Clinical Trials, Phase I as Topic; D004353:Drug Evaluation, Preclinical; D015507:Drugs, Investigational; D005544:Forecasting; D020719:Glucuronides / Q000378:metabolism; D006801:Humans; D006913:Hydroxysteroid Dehydrogenases; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy / Q000652:urine; D007413:Intestinal Mucosa / Q000187:drug effects / Q000378:metabolism; D008562:Membrane Glycoproteins; D015394:Molecular Structure; D009284:Naphthols / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D045002:3-alpha-Hydroxysteroid Dehydrogenase (B-Specific)
D000924:Anticholesteremic Agents; D001647:Bile Acids and Salts; D002352:Carrier Proteins; D015507:Drugs, Investigational; D020719:Glucuronides; D006913:Hydroxysteroid Dehydrogenases; D008562:Membrane Glycoproteins; D009284:Naphthols; C037643:bile acid binding proteins; C106517:S 8921; C435496:AKR1C2 protein, human; D045002:3-alpha-Hydroxysteroid Dehydrogenase (B-Specific)